Stay updated on Aldesleukin and Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedUpdated the page revision from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedA unified 'Locations' section was added listing Illinois, Indiana, Massachusetts, New Jersey, and New York, replacing the previous separate 'XYZ Locations' headers. The page revision updated to v3.3.3 and the 'HHS Vulnerability Disclosure' link was removed.SummaryDifference0.6%

- Check59 days agoChange DetectedPublication notes were adjusted to specify that PubMed-listed publications are auto-generated and may not be related to the study. The revision tag changed from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check66 days agoChange DetectedThe notice about lapse in government funding and NIH operating status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check80 days agoChange DetectedThe update involves formatting and layout adjustments to the study details page and does not modify core trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check108 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference2%

Stay in the know with updates to Aldesleukin and Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page.